Article thumbnail

Computational Models of HIV-1 Resistance to Gene Therapy Elucidate Therapy Design Principles

By Sharon Aviran, Priya S. Shah, David V. Schaffer and Adam P. Arkin

Abstract

Gene therapy is an emerging alternative to conventional anti-HIV-1 drugs, and can potentially control the virus while alleviating major limitations of current approaches. Yet, HIV-1's ability to rapidly acquire mutations and escape therapy presents a critical challenge to any novel treatment paradigm. Viral escape is thus a key consideration in the design of any gene-based technique. We develop a computational model of HIV's evolutionary dynamics in vivo in the presence of a genetic therapy to explore the impact of therapy parameters and strategies on the development of resistance. Our model is generic and captures the properties of a broad class of gene-based agents that inhibit early stages of the viral life cycle. We highlight the differences in viral resistance dynamics between gene and standard antiretroviral therapies, and identify key factors that impact long-term viral suppression. In particular, we underscore the importance of mutationally-induced viral fitness losses in cells that are not genetically modified, as these can severely constrain the replication of resistant virus. We also propose and investigate a novel treatment strategy that leverages upon gene therapy's unique capacity to deliver different genes to distinct cell populations, and we find that such a strategy can dramatically improve efficacy when used judiciously within a certain parametric regime. Finally, we revisit a previously-suggested idea of improving clinical outcomes by boosting the proliferation of the genetically-modified cells, but we find that such an approach has mixed effects on resistance dynamics. Our results provide insights into the short- and long-term effects of gene therapy and the role of its key properties in the evolution of resistance, which can serve as guidelines for the choice and optimization of effective therapeutic agents

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2920833
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). Adoptive immunotherapy: good habits instilled at youth have long-term benefits.
  2. (1995). Age, Thymopoiesis, and CD4+ T-Lymphocyte Regeneration after Intensive Chemotherapy.
  3. (2008). An HIV Vaccine – Challenges and Prospects.
  4. (2004). AntisenseMediated Inhibition of Human Immunodeficiency Virus (HIV) Replication by Use of an HIV Type 1-Based Vector Results in Severely Attenuated Mutants Incapable of Developing Resistance.
  5. (2009). Antiviral Gene Therapy Antiviral Strategies.
  6. (2005). Antiviral RNAi therapy: emerging approaches for hitting a moving target.
  7. (2003). Barriers to nonviral gene delivery.
  8. (1997). Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215.
  9. (2007). Building an HIV-Proof Immune System.
  10. (2006). Can gene delivery close the door to HIV-1 entry after escape?
  11. (2010). Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O6-methylguanine-DNA methyltransferaseP140K.
  12. (2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness.
  13. (2007). Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC.
  14. (2008). Comprehensive Assessment and Mathematical Modeling of T Cell Population Dynamics and Homeostasis.
  15. (2005). Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape.
  16. (2005). CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection.
  17. (1997). Decay characteristics of HIV-1-infected compartments during combination therapy.
  18. (1999). Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans.
  19. Effros RB (2004) Genetic Manipulation of Telomerase in HIV-Specific CD8+ T Cells: Enhanced Antiviral Functions Accompany the Increased Proliferative Potential and Telomere Length Stabilization.
  20. (2000). Elena SF, Moya A
  21. (2009). Engineering lymphocyte subsets: tools, trials and tribulations.
  22. (2008). Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases.
  23. (2000). Estimating relative fitness in viral competition experiments.
  24. (2001). Evidence for Increased T Cell Turnover and Decreased Thymic Output in HIV Infection.
  25. (2004). Evidence for Positive Epistasis in HIV-1.
  26. (2006). Evolutionary dynamics: exploring the equations of life. Cambridge Mass.:
  27. (2009). Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis.
  28. (2000). Factors influencing T-cell turnover in HIV-1-seropositive patients.
  29. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways.
  30. (2010). Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo.
  31. (2006). Gene therapy for HIV infection: what does it need to make it work?
  32. (1997). Gene therapy of T helper cells in HIV infection: Mathematical model of the criteria for clinical effect.
  33. (2006). Gene transfer in humans using a conditionally replicating lentiviral vector.
  34. (2006). Gene-Based Immunotherapy for Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome.
  35. (2007). Genetic therapies against HIV.
  36. (2005). Hematopoietic Stem Cell Transduction and Amplification in Large Animal Models.
  37. (2004). HIV Drug Resistance.
  38. (2008). HIV evades RNA interference directed at TAR by an indirect compensatory mechanism.
  39. (1996). HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.
  40. Ho DD (2003) HIV-1 dynamics in vivo: implications for therapy.
  41. (2004). Human Immunodeficiency Virus Type 1 Escapes from RNA Interference-Mediated Inhibition.
  42. (2006). Impact of gene-modified T cells on HIV infection dynamics.
  43. (2002). In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: Why are CD4+ but not CD8+ T cells depleted?
  44. (2004). Inhibition of Human Immunodeficiency Virus Type 1 Entry in Cells Expressing gp41-Derived Peptides.
  45. (2005). Long-Term Inhibition of HIV1 Infection in Primary Hematopoietic Cells by Lentiviral Vector Delivery of a Triple Combination of Anti-HIV shRNA, Anti-CCR5 Ribozyme, and a Nucleolar-Localizing TAR Decoy.
  46. (1995). Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.
  47. (2002). Maintaining the norm: T-cell homeostasis.
  48. (2004). MicroRNAs Modulate Hematopoietic Lineage Differentiation.
  49. (2006). Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay.
  50. (2009). Modeling HIV persistence, the latent reservoir, and viral blips.
  51. (2002). Modelling viral and immune system dynamics.
  52. (2003). Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty.
  53. (2007). Optimal timing and duration of induction therapy for HIV-1 infection.
  54. (2006). Optimization and Functional Effects of Stable Short Hairpin RNA Expression in Primary Human Lymphocytes via Lentiviral Vectors.
  55. (2009). Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.
  56. (2005). Primary Human T Lymphocytes Engineered with a Codon-Optimized IL-15 Gene Resist Cytokine Withdrawal-Induced Apoptosis and Persist Long-Term in the Absence of Exogenous Cytokine.
  57. (2000). Production of resistant HIV mutants during antiretroviral therapy.
  58. (2007). Progress and prospects: RNA-based therapies for treatment of HIV infection.
  59. (2009). Protein Scaffold and Expression Level Determine Antiviral Activity of Membrane-Anchored Antiviral Peptides.
  60. (1999). Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.
  61. (2004). Recombination in HIV and the evolution of drug resistance: for better or for worse?
  62. (2002). Redundancy, antiredundancy, and the robustness of genomes.
  63. (2006). Removal of Arginine 332 Allows Human TRIM5a To Bind Human Immunodeficiency Virus Capsids and To Restrict Infection.
  64. (2010). Safety and feasibility of lentiviral vector-modified CD34+ cells in the setting of autologous transplantation for AIDS-related lymphoma.
  65. (2005). Selection and characterization of HIV-1 showing reduced susceptibility to the nonpeptidic protease inhibitor tipranavir.
  66. (2006). Silencing of HIV-1 with RNA interference: a multiple shRNA approach.
  67. (2007). Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in nonhuman primates.
  68. (2006). Survival of the fittest: in vivo selection and stem cell gene therapy.
  69. (2005). T Lymphocytes Transduced with a Lentiviral Vector Expressing
  70. (2006). T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.
  71. (2004). Tcell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120.
  72. (2009). The Challenge of Finding a Cure for HIV Infection.
  73. (2003). Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection.
  74. (2002). Thymic regeneration: teaching an old immune system new tricks.
  75. (2009). Timing the emergence of resistance to anti-HIV drugs with large genetic barriers.
  76. (2006). to the Protease Inhibitor Tipranavir.
  77. (1995). Towards a general function describing t cell proliferation.
  78. (2001). Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology.
  79. (2008). Updated prevalence of genotypic resistance among HIV-1 positive patients naı ¨ve to antiretroviral therapy: a single center analysis.
  80. (1995). Viral dynamics in human immunodeficiency virus type 1 infection.
  81. (2000). Virus dynamics: mathematical principles of immunology and virology.